Darzalex' 2020 sales reach prognosis peak
Johnson & Johnson's sales of the Genmab-developed drug Darzalex has continued its growth in Q4, and so, the drug has reached the upper end of expected sales.
Johnson & Johnson's sales of the Genmab-developed drug Darzalex has continued its growth in Q4, and so, the drug has reached the upper end of expected sales.
US Decibel Therapeutics gets listed in the US, where the company – which has raised million-dollar figures on four prior occasions – plans to fetch USD 75m for the development of a pharmaceutical treatment for reduced hearing.
Leo Pharma is negotiating confidentially with an investor circle interested in buying into the firm, learns Børsen. The sales process is moving in the right direction, according to Leo Foundation.
After complaints from NGOs the EU's ombudsman enters the case concerning public access to the vaccine contracts which the union has signed with multiple pharmaceutical companies.
Italy plans to sue Pfizer, which is unable to meet planned amounts of vaccines, but Denmark will not be doing the same, according to Danish Prime Minister Mette Frederiksen.
Financial services company Jefferies has set its eye on Danish hearing aid company Demant as a firm which can potentially perform well on share price.
Conspiracy theories abound when vaccine manufacturers get away with secret EU deals.
Biohaven has failed its trial program with a treatment for Alzheimer's disease in phase II-III, but hopes follow-up analyses will have promising outcome, so the firm will not have to ditch the drug.
Tuesday EMA informed that December attack files have been leaked. The specific nature of the documents is unknown but the involved parties may have cause for concern.
Hearing aid company WS Audiology is the first established industry player to present a hearing aid designed as the type of earbuds which for example Apple has been hugely successful with. The goal is to attract younger customers to the shop, according to the firm, which calls the new product an "actual paradigm shift".
Due to higher discount levels than expected, the EU migraine market may soon be worth as much as the US market, according to Teva CEO Kåre Schultz.
Eli Lilly has sent supplemental new drug application to US FDA for use of diabetes drug Jardiance.